Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials

Conclusion Performance status, LDH, albumin and histological type (tumour aggressiveness) appear to be the most relevant prognostic factors for enrolling Phase I participants with relapsed or refractory lymphoma. 39% of the patients experienced a first high-grade toxic event after the dose-limiting toxicity period, suggesting that the conventional concept of dose-limiting toxicity (designed for chemotherapy) should be redefined in the era of modern cancer therapies.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research